Skip to main content
欧康医药 logo

欧康医药 — Investor Relations & Filings

Ticker · 920230 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 373 across all filing types
Latest filing 2025-01-21 Governance Information
Country CN China
Listing Beijing Stock Exchange 920230

About 欧康医药

https://www.okaypharm.com/

Oukang Pharmaceutical specializes in the research, development, and large-scale production of natural plant extracts, with a primary focus on citrus-derived flavonoids. The company’s core product portfolio includes high-purity ingredients such as Hesperidin, Diosmin, Methyl Hesperidin, and Neohesperidin Dihydrochalcone (NHDC). These products serve as essential raw materials for the global pharmaceutical, nutraceutical, food and beverage, and cosmetic sectors. Utilizing advanced extraction and purification technologies, the company maintains rigorous quality control standards to ensure compliance with international regulatory requirements. Its operations emphasize the industrialization of plant-based chemical derivatives to support diverse health and wellness applications.

Recent filings

Filing Released Lang Actions
舆情管理制度
Governance Information Classification · 95% confidence The document is titled as a "舆情管理制度" (Public Opinion Management System) issued by the company's board. It details the company's internal policy and procedures for managing public opinion and media-related crises, including organizational structure, responsibilities, principles, and confidentiality obligations. It is a formal internal governance document approved by the board on a specific date (January 22, 2025). There are no financial statements, earnings data, or regulatory filings such as audit reports or annual reports. It is not an announcement of a report but a governance policy document. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-01-21 Chinese
第四届董事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the sixth meeting of the fourth board of directors of Chengdu Oukang Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda, and voting results on a specific company policy (舆情管理制度 - Public Opinion Management System). There is no financial data, no mention of annual or quarterly reports, no audit information, no shareholder voting results at a general meeting, and no mention of dividends or capital changes. The document is clearly a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is short (1010 characters), and it is not an announcement of a report publication but the actual meeting resolution content. Therefore, the correct classification is MANG with high confidence.
2025-01-21 Chinese
2024年年度业绩预告公告
Earnings Release Classification · 95% confidence The document is a 2024 annual performance forecast announcement by Chengdu Oukang Pharmaceutical Co., Ltd. It provides preliminary financial data for the full year 2024, including net profit estimates and reasons for performance changes. It explicitly states that the data are preliminary, unaudited, and subject to the final 2024 annual report. The document is short (848 characters) and serves as a forecast or earnings preview rather than a full annual report. It does not contain audited financial statements or comprehensive financial analysis. Therefore, it is best classified as an Earnings Release (ER), which covers initial announcements of periodic financial results or forecasts. FY 2024
2025-01-19 Chinese
关于变更签字注册会计师的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the change of the signing certified public accountant (CPA) for the company's 2024 audit. It details the replacement of the project partner and signing CPA due to retirement, provides background information on the new signing CPA, and confirms no impact on the audit work. The document does not contain the audit report itself or detailed financial data but is a formal notification about the auditor change. This fits the category of Audit Report / Information (AR), which includes standalone audit reports and related information such as changes in auditors. The document length is short and focused on auditor change, not a full annual report or certification letter. Therefore, the classification is AR with high confidence. FY 2024
2025-01-14 Chinese
关于完成工商变更登记并取得营业执照的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the completion of a business registration change and the obtaining of a new business license by Chengdu Oukang Pharmaceutical Co., Ltd. It details the change in registered capital and confirms no other changes in business registration items. The document is short (1119 characters) and serves as a formal notification of a corporate registration update rather than a financial report or detailed filing. There is no financial data, audit information, or management discussion. It is not a report but an official announcement of a corporate change. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-12-05 Chinese
股票解除限售公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the lifting of stock trading restrictions (解除限售公告) for certain shares held by former directors, supervisors, and senior management personnel. It details the number of shares becoming tradable, the reasons for lifting restrictions, and the updated share capital structure. The document is short (2000 characters) and focuses on share status changes rather than financial results or management changes. It does not contain financial statements or earnings data, nor is it a report or presentation. This type of announcement fits the category of Share Issue/Capital Change (SHA), as it relates to changes in share capital availability and trading status.
2024-11-18 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.